Zydus Lifesciences Limited has received final approval from the United States Food and Drug Administration (USFDA) to manufacture and market Estradiol Transdermal System USP, 0.014 mg/day, the company announced through an exchange filing.
Estradiol transdermal system is indicated for prevention of postmenopausal osteoporosis. The drug will be manufactured at the group’s formulation manufacturing facility in Moraiya, Ahmedabad (India).
Estradiol Transdermal System USP, 0.014 mg/day (weekly) had annual sales of USD 1.9 mn in the United States (IQVIA MAT Feb. 2023).
The group now has 363 approvals and has so far filed over 440* ANDAs since the commencement of the filing process in FY 2003-04.
Bombay HC Orders Expert Committee To Curb Urban Chaos In Badlapur, Ensuring Systematic Town Planning
Navi Mumbai Demolition Case: Bombay HC Seeks Report To Determine If Plea Qualifies As PIL
Mumbai Environment Alert: BMC To Enforce Stricter Pollution Penalties On Construction Sites From November
26/11 Mumbai Terror Attack Case: 'Won’t Pass Any Order On Fahim Ansari’s Police Clearance Without Granting Access To State Material,' Says Bombay HC
